What is THX Pharma Société Anonyme (ALTHX.PA) stock price today?

THX Pharma Société Anonyme (ALTHX.PA) is currently trading at $4.27, down 6.77% today.

PAR · —

THX Pharma Société Anonyme (ALTHX.PA) Stock

$4.27 -6.77% PAR: ALTHX.PA —

Valuation

Metric	Value
Price	$4.27
Market Cap	—
P/E Ratio	—
P/B Ratio	—
P/S Ratio	—
EPS (TTM)	—
52-Week High	$5.10
52-Week Low	$1.49
Dividend Yield	—

Financials & Margins

Metric	Value
ROE	—
ROA	—
ROCE	—
Gross Margin	—
Operating Margin	—
Net Margin	—
Debt/Equity	—
Current Ratio	—

Latest News

A $500,000 IRA Went Through Probate Instead of to the Kids, Because of a Beneficiary Form From 1998. 24/7 Wall St. · Aug 15, 2026 He Spent His 60s Quietly Moving His IRA Into a Roth. At 73, When the IRS Showed Up to Dictate His Withdrawals, There Was Nothing Left to Tax 24/7 Wall St. · Aug 15, 2026 Delaying Social Security Until Age 70 Isn’t Always the Best Choice. Here’s When Claiming Early Wins 24/7 Wall St. · Aug 15, 2026 Ocala Is Quietly Becoming Florida’s Retirement Capital and Homes Are Still Under $300,000 24/7 Wall St. · Aug 15, 2026 Everything announced at Made by Google 2026: Pixel 11 lineup, Pixel Watch 5, and Pixel Tag Digital Trends · Aug 15, 2026

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-13.05
FCF Yield	—
Quick Ratio	2.32
Interest Coverage	—
Return 1Y	63.86%
Return 3Y	241.14%
Return 5Y	-47.80%

Ownership

Insiders Held10.79%

Institutions Held7.93%

Institutions Float Held8.89%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AELIS.PAAelis Farma SA	$1.07	-3.60%	-2.28	$14.59M	0.00%
ALBIO.PABiosynex SA	$0.93	-7.00%	-0.23	$17.14M	0.00%
ALBLU.PABluelinea Société Anonyme	$0.19	+0.00%	-2.71	$5.03M	0.00%
ALIKO.PAIkonisys S.A.	$1.42	-1.39%	-5.26	$22.47M	0.00%
ALINS.PAIntrasense S.A.	$0.21	+0.00%	-0.01	$11.06M	0.00%

About THX Pharma Société Anonyme

Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.

THX Pharma Société Anonyme is led by CEO Mathieu Charvériat, employs 12 people, headquartered in Lyon, FR, publicly traded since 2017.

over the past 52 weeks the stock has ranged between $1.49 and $5.10, and currently trades 16.3% below its 52-week high.

Official website: www.theranexus.com